Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3625-3627

  Ortiz González, Jorge ^a,b   Alvarez Aguila, Nora Patricia ^a   Medina Castro, Juan Manuel ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

CA 19 9; Differentiation; Pancreatic adenocarcinoma; Tumor markers

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; BILE DUCT OBSTRUCTION; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; CANCER GRADING; CELL METABOLISM; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; JAUNDICE; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TISSUE DIFFERENTIATION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; BILIRUBIN; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 23344443156     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mam DV, Edwards R, Ho S, Lau WY and Glazer G: Elevated tumor marker Ca 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26: 474-479, 2000.
2. Barkin JS and Goldstein JA: Diagnostic approach to pancreatic cancer. Gastroenterol Clin N Am 28: 457-481, 1999.
3. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gómez E and Robles-Díaz G: Does cholestasis change the clinical usefulness of CA 19-9 in pancreatobiliary cancer? Rev Invest Clin 53: 511-517, 2001.
4. Brand R: Diagnosis of pancreatic cancer. Cancer J 5: 510-522, 2001.
5. Posner MR and Mayer RJ: The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin N Am 8: 533-553, 1994.
6. Schlieman MG, Ho HS and Bold RJ: Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138: 951-956, 2003.
7. Peterli R, Meyer Wyss B, Herzog U et al: CA 19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 129: 77-79, 1999.
8. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM and Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6: 462-468, 1988.
9. Rosty C and Goggins M: Early detection of pancreatic carcinoma. Hematol Oncol Clin N Am 16: 37-52, 2002.
10. Rocha Lima CM and Centeno B: Update on pancreatic cancer. Curr Opin Oncol 14: 424-430, 2002.